Spatiotemporal Tumor Analytics to Guide Sequential Targeted Inhibitors with Immunotherapy
Official title: Spatiotemporal Tumor Analytics for Guiding Sequential Targeted-Inhibitor: Immunotherapy Combinations (ST-Analytics)
Funded at Institute for Systems Biology · NIH-11415801 · Data updated 2026-11-12
A national team is testing whether giving targeted cancer drugs first and then immunotherapy works better than giving them together, using patient data and animal models to learn the best timing.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Institute for Systems Biology NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 22, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $2,497,679 |
| NIH project number | 5U54CA274509-05 |
| Project ID | NIH-11415801 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients with cancers where targeted inhibitors and immunotherapies are used, including melanoma and metastases scenarios.
✕Less likely to help
Patients whose cancer biology does not respond to sequential strategies or who cannot tolerate immunotherapy may see no benefit.
What this research studies
This program seeks to uncover the best sequence and timing for combining targeted inhibitors with immunotherapy to improve cancer treatment. Researchers will analyze past patient data and run tumor models to understand how order and timing affect effectiveness and resistance, with a focus on melanoma and brain metastases. The project brings together experts from the Institute for Systems Biology and UCLA to build a data-driven framework that can guide future clinical trials. The work aims to translate complex findings into clearer strategies that doctors can apply when planning sequential therapies for patients.
Why it matters
Potential benefit: If successful, the approach could lead to more effective cancer treatments by optimizing the sequence of drugs, potentially improving response rates and delaying resistance.
How similar studies have gone: Previous work in melanoma supports the idea that sequencing can influence response, but translating this into a reliable clinical framework is still being established.
Where this research is happening
-
Institute for Systems Biology
Seattle, United States Active
Researchers
- Principal investigator: Heath, James R. — Institute for Systems Biology
- Study coordinator: Heath, James R.
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.